Table 3.

Viral responses to AdV-specific T cells

Pt. no.	Viral disease	Duration of previous standard therapy	Line infused	HLA match (low-resolution) to recipient	No. of infusions	Best response by 6 wk	Comments
18	AdV	Cidofovir 33 d	C2582	1/6	1	PR	PR based on AdV in stool Resolution of elevated liver enzymes
21	AdV	Cidofovir 40 d	C2339	2/6	1	CR	Sustained CR
25	AdV	Cidofovir 38 d	C3466	2/6	1	PR	CR after day 42
26	AdV	Renal function precluded use of cidofovir	C3528	1/6	1	NR	Died at 14 d postinfusion of progressive AdV infection
38	AdV	Cidofovir 36 d	C3005	2/6	2	PR	CR after day 42
40	AdV	Renal function precluded use of cidofovir	C2339	2/6	1	NR	Died day 9 post-VST infusion of progressive AdV infection
52	AdV	Renal function precluded use of cidofovir	C3889	1/6	1	PR	CR after day 42
59	AdV	Cidofovir 29 d	C2457	1/6	1	CR	Sustained CR
68	AdV	Cidofovir 20 d	C3889	1/6	3	PR	PRs but recurrences
69	AdV/CMV	Cidofovir 5 d - unable to tolerate because of renal function	C3629	4/6	1	CR	Sustained CR/AdV; also CR/CMV and resolution CMV colitis
70	AdV	Cidofovir 3 mo	C2270	2/6	1	N/E	Died at 6 d postinfusion of progressive AdV infection
76	AdV	Cidofovir 9 d	C2457	3/6	1	CR	Sustained CR
81	AdV	Cidofovir 3 wk	C3005	3/6	1	NR	Died day 19 post-VST infusion of persistent AdV infection
86	AdV	Cidofovir 20 d	C2339	3/6	2	PR	PR but recurrence, died day 18 post-VST of AdV and paraflu
88	AdV	Cidofovir 7 d	C4378	2/6	1	PR	Sustained CR
94	AdV	Cidofovir 8 d	C3617	2/6	1	CR	Sustained CR
96	AdV	Cidofovir 14 d	C2353	2/6	1	CR	Sustained CR
97	AdV/CMV	Cidofovir 31 d	C3629	2/6	1	CR	Sustained CR; Also CR of CMV

Abbreviations are explained in Table 2.